Using Real-World Data to Assess the Association of Retinal Detachment With Topical Pilocarpine Use

被引:0
|
作者
Elhusseiny, Abdelrahman m. [1 ,2 ]
Chauhan, Muhammad z. [1 ]
Jabbehdari, Sayena [1 ]
Alshammari, Nayef [1 ]
Jong, Sarah [1 ]
Phillips, Paul h. [1 ]
Sallam, Ahmed b. [1 ,3 ]
机构
[1] Univ Arkansas Med Sci, Harvey & Bernice Jones Eye Inst, Dept Ophthalmol, Little Rock, AR USA
[2] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA USA
[3] Ain Shams Univ Hosp, Dept Ophthalmol, Cairo, Egypt
关键词
PRESBYOPIA; MIOTICS;
D O I
10.1016/j.ajo.2024.10.035
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
center dot PURPOSE: To examine the association between topical pilocarpine and the risk of new-onset rhegmatogenous retinal detachment (RRD). center dot DESIGN: Retrospective clinical cohort study. center dot METHODS: We used an aggregated electronic health records research network, TriNetX, to examine the risk of RRD (ICD-10: H33.0x) following the initiation of pilocarpine. The primary study group included adult patients over 40 years who received topical pilocarpine (1.25% or any dose with the exclusion of other indications) for the first time. Our control group consisted of patients with presbyopia who were started on artificial tears and had no history of topical pilocarpine use during the study period. We matched both cohorts using propensity score matching (PSM) based on demographics, systemic comorbidities, and known risk factors for RRD. center dot RESULTS: After matching, the three-month risk of RRD was significantly higher in the pilocarpine group (0.53%) compared to the control (0.25%) (RR: 2.18, 95% CI: 1.07-4.45, P = .03). The 6-month risk of RRD remained elevated at 0.60% in the study group versus 0.31% in the control group (RR: 1.93, 95% CI: 1.013.67, P = .04). At one year, the risk increased to 0.78% in the pilocarpine group and 0.33% in the control group (RR: 2.33, 95% CI: 1.28-4.27, P = . 005). A Cox proportional hazards model indicated that pilocarpine use was associated with a 3.14-fold increased risk of RRD (95% CI: 1.66-5.93, P < . 001) compared to controls after adjusting for demographics and comorbidities. Additional risk factors for RRD included male sex (aHR: 2.36, P = . 001), myopia (aHR: 2.36, P = . 001), vitreous degeneration (aHR: 2.22, P = . 020), lattice degen eration (aHR: 3.71, P = . 010), and pseudophakia (aHR: 3.48, P < . 001). center dot CONCLUSIONS: Our study quantified the increased risk of RRD associated with topical pilocarpine use. (Am J Ophthalmol 2025;271: 1-6. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [21] Use of national databases: interpreting treatment outcomes using real-world data
    Subramanian, Melanie
    Kozower, Benjamin D.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : E828 - E829
  • [22] Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report
    Garrison, Louis P., Jr.
    Neumann, Peter J.
    Erickson, Pennifer
    Marshall, Deborah
    Mullins, Daniel
    VALUE IN HEALTH, 2007, 10 (05) : 326 - 335
  • [23] Real-World Data Difficulty Estimation with the Use of Entropy
    Juszczuk, Przemyslaw
    Kozak, Jan
    Dziczkowski, Grzegorz
    Glowania, Szymon
    Jach, Tomasz
    Probierz, Barbara
    ENTROPY, 2021, 23 (12)
  • [24] REGISTRY: ITS USE IN REAL-WORLD DATA COLLECTION
    Pan, Y., I
    Dieck, G.
    Stemhagen, A.
    VALUE IN HEALTH, 2014, 17 (03) : A203 - A203
  • [25] The use of real-world data in cancer drug development
    Skovlund, E.
    Leufkens, H. G. M.
    Smyth, J. F.
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 69 - 76
  • [26] The use of real-world data/evidence in regulatory submissions
    Song, Fuyu
    Zang, Chenxuan
    Ma, Xinyi
    Hu, Sifan
    Sun, Qiqing
    Chow, Shein-Chung
    Sun, Hongqiang
    CONTEMPORARY CLINICAL TRIALS, 2021, 109
  • [27] Registry: Its Use in Real-World Data Collection
    Pan, Irene
    Dieck, Gretchen
    Stemhagen, Annette
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 124 - 125
  • [28] Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective
    Chen, Jie
    Gruber, Susan
    Lee, Hana
    Chu, Haitao
    Lee, Shiowjen
    Tian, Haijun
    Wang, Yan
    He, Weili
    Jemielita, Thomas
    Song, Yang
    Tamura, Roy
    Tian, Lu
    Zhao, Yihua
    Chen, Yong
    van Der Laan, Mark
    Nie, Lei
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025, 117 (04) : 946 - 960
  • [29] Data Science Methods for Real-World Evidence Generation in Real-World Data
    Liu, Fang
    ANNUAL REVIEW OF BIOMEDICAL DATA SCIENCE, 2024, 7 : 201 - 224
  • [30] Strategies to Turn Real-world Data Into Real-world Knowledge
    Hong, Julian C.
    JAMA NETWORK OPEN, 2021, 4 (10)